SOSLAB’s LiDAR ‘ML’ for Automotive Wins CES Innovation Award
12.1.2021 16:00:00 EET | Business Wire | Press release
SOSLAB that specializes in LiDAR, won the CES 2021 Innovation Awards at the world's largest electronics exhibition 'CES 2021,' for its Solid-state LiDAR ‘ML’ for automotive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005486/en/
Professional LiDAR Sensor provider SOSLAB won the CES 2021 Innovation Awards for its Solid-state LiDAR ML for automotive. The Solid-state LiDAR ML for autonomous vehicles won the Innovation Awards in the Vehicle Intelligence and Transportation category. This award recognizes the excellence of this product ML: Compact LiDAR without moving parts inside which enables simpler vehicle sensor deployment in terms of size, weight and stability. ML is easy to mass-produce with a simple structural design which is expected to attract attention in the automotive LiDAR market. ML will be supplied to strategic partners only, launching prototype products in the global market at CES 2021. More information on ML can be found at the SOSLAB booth at the CES 2021 exhibition held online from January 11th to 14th. (Photo: Business Wire)
The CES Innovation Awards are awarded by about 50 expert judges who select the most innovative products in 28 categories each year. The products selected for this innovation award are displayed at the CES Innovation Showcase from January 11th.
SOSLAB’s Solid-state LiDAR ‘ML’ for autonomous vehicles won the Innovation Awards in the Vehicle Intelligence & Transportation category. This award recognizes the excellence of this product ML: Compact LiDAR without moving parts inside which enables simpler vehicle sensor deployment in terms of size, weight and stability.
The mechanical type of LiDAR currently used for research on autonomous driving has a limitation in mass production due to the system complexity caused by the moving components; ML is easy to mass-produce with a simple structural design which is expected to attract attention in the automotive LiDAR market.
ML was previously unveiled at KES2020 held at the COEX Exhibition Hall last year and will be supplied to strategic partners only, launching prototype products in the global market at CES 2021. More information on ML can be found at the SOSLAB booth at the CES 2021 exhibition held online from January 11th to 14th.
SOSLAB’s CEO, Jiseong Jeong said, “SOSLAB will become a company that makes the world smarter with LiDAR. Along with the verification of ML's technical excellence, we plan to complete product performance verification and auto-grade qualification by the second half of this year by securing additional capital with the goal of mass production of Solid-state LiDARs in 2022. SOSLAB will grow into a company that leads the global LiDAR market by commercializing LiDAR for vehicles.”
See SOSLAB's Compact 3D Solid-state LiDAR ‘ML’ video on
https://youtu.be/o3hSOnNKlDw
Additional Info.
Website:
http://soslab.co/
YouTube:
https://www.youtube.com/soslab
About SOSLAB
SOSLAB specializes in LiDAR (Light Detection and Ranging), which measures the distance to an object using light. We develop and supply 2D and 3D LiDARs to the market, growing into a global company by successfully developing Solid-state LiDAR for automotive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005486/en/
Contact information
SOSLAB
Ellie Yeojin Kim / Marketing Manager
+82-62-973-5051
ellie.kim@soslab.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom